Scholarlink

Background <p>The high-risk human papillomavirus 16/18 (HR HPV 16/18) is substantial causes of high morbidity and mortality among women. Already infected women are still suffering from cervical cancer and cervical intraepithelial neoplasia (CIN) due to the absence of a therapeutic vaccine. The most potent therapeutic vaccine is expected to induce both cellular and humoral immunity.</p> Objective <p>The aim of this review is to systematically assess novel therapeutic vaccine development strategies targeting high-risk HPV16/18-E6/7 oncoproteins, their immunogenicity, and efficacy associated with cervical cancer and CIN.</p> Methods <p>Articles were systematically searched in Scopus, PubMed, Hinari, and Google Scholar from 2014 to 2024. Only original articles conducted in human clinical trials were included. The Joanna Briggs Institute (JBI) Critical Appraisal Tools for Systematic Reviews Checklist for Systematic Reviews and Research Syntheses (<a href="http://joannabriggs.org/research/critical-appraisal-tools.html">http://joannabriggs.org/research/critical-appraisal-tools.html</a>) were used to assess risk of bias in included studies. Five authors worked independently to avoid risks of bias. The data are presented in the form of tables and narratives. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA, 2020) guidelines were used to select studies.</p> Results <p>Out of 555 pertinent studies searched, only 22 articles were included. Main outcomes observed in almost all enrolled patients were histopathological waning from high grade CIN to low grade, generation of HR HPV 16/18-specific humoral and cellular immune responses, viral load clearance, tumor regression, and virus-specific interferon and interleukin. Therapeutic vaccines administered with an adjuvant showed higher immunogenicity and efficacy than those without an adjuvant. Moreover, different strategies of HR HPV 16/18 vaccine development demonstrated varying immunogenicity and efficacy against cervical cancer and CIN.</p> Discussion <p>The development of novel HR HPV 16/18 therapeutic vaccine strategies, their immunogenicity, and efficacy is very promising for cervical cancer and CIN therapy. The novel HR HPV 16/18 Therapeutic vaccines need to include different immune targets and adjuvants. Further studies are required to develop an effective HR HPV 16/18 therapeutic vaccine strategy, boost their immunogenicity and efficacy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Novel therapeutic vaccine development strategies targeting high risk HPV16/18-E6/7 oncoproteins, their immunogenicity, and efficacy associated with cervical intraepithelial neoplasia and cervical cancer: a systematic review

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年5月16日

查看全文
  • Zigale Hibstu Teffera,
  • Desalegn Abebaw,
  • Yibeltal Akelew,
  • Mekuriaw Belayneh,
  • Bewket Mesganaw Shitie,
  • Bantegzie Selabat,
  • Samrawit Tefera,
  • Habtamu Belew,
  • Lealem Gedefaw

摘要

Background

The high-risk human papillomavirus 16/18 (HR HPV 16/18) is substantial causes of high morbidity and mortality among women. Already infected women are still suffering from cervical cancer and cervical intraepithelial neoplasia (CIN) due to the absence of a therapeutic vaccine. The most potent therapeutic vaccine is expected to induce both cellular and humoral immunity.

Objective

The aim of this review is to systematically assess novel therapeutic vaccine development strategies targeting high-risk HPV16/18-E6/7 oncoproteins, their immunogenicity, and efficacy associated with cervical cancer and CIN.

Methods

Articles were systematically searched in Scopus, PubMed, Hinari, and Google Scholar from 2014 to 2024. Only original articles conducted in human clinical trials were included. The Joanna Briggs Institute (JBI) Critical Appraisal Tools for Systematic Reviews Checklist for Systematic Reviews and Research Syntheses (http://joannabriggs.org/research/critical-appraisal-tools.html) were used to assess risk of bias in included studies. Five authors worked independently to avoid risks of bias. The data are presented in the form of tables and narratives. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA, 2020) guidelines were used to select studies.

Results

Out of 555 pertinent studies searched, only 22 articles were included. Main outcomes observed in almost all enrolled patients were histopathological waning from high grade CIN to low grade, generation of HR HPV 16/18-specific humoral and cellular immune responses, viral load clearance, tumor regression, and virus-specific interferon and interleukin. Therapeutic vaccines administered with an adjuvant showed higher immunogenicity and efficacy than those without an adjuvant. Moreover, different strategies of HR HPV 16/18 vaccine development demonstrated varying immunogenicity and efficacy against cervical cancer and CIN.

Discussion

The development of novel HR HPV 16/18 therapeutic vaccine strategies, their immunogenicity, and efficacy is very promising for cervical cancer and CIN therapy. The novel HR HPV 16/18 Therapeutic vaccines need to include different immune targets and adjuvants. Further studies are required to develop an effective HR HPV 16/18 therapeutic vaccine strategy, boost their immunogenicity and efficacy.